TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized and Placebo-Controlled Double-Blind Multicentre Study to Determine the Efficacy and Safety of VSL#3 Probiotic Food Supplement Mixture in Prevention of Endoscopic Recurrence in Crohn's Disease Patients With Ileocolonic Surgical Resection and Small Intestine to Colon Anastomosis.
Brief Summary: This randomized placebo-controlled double-blind, multi-centre trial will determine the efficacy of the probiotic VSL#3 in the prevention of Crohn's disease development following surgical resection and re-anastomosis. A total of 120 patients will be randomly assigned in a 1:1 ratio to receive VSL#3 or placebo for 90 days. Patients who respond to study treatment, as defined by the absence of a severe endoscopic recurrence at day 90, will be offered open-label VSL#3 for an additional 9 months.


Options:
A: Arm Label: Infliximab; Type: EXPERIMENTAL; Interventions: Biological: Infliximab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Infliximab; Assigned to Arm(s): Infliximab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Probiotic - VSL#3; Assigned to Arm(s): N/A
C: Arm Label: Azathioprine; Type: EXPERIMENTAL; Interventions: Drug: Azathioprine, Drug: Mesalazine placebo | Arm Label: Mesalazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalazine, Drug: Azathioprine placebo | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Azathioprine | Intervention Type: DRUG; Name: Mesalazine; Assigned to Arm(s): Mesalazine | Intervention Type: DRUG; Name: Azathioprine placebo; Assigned to Arm(s): Mesalazine | Intervention Type: DRUG; Name: Mesalazine placebo; Assigned to Arm(s): Azathioprine
D: Arm Label: Active arm; Type: ACTIVE_COMPARATOR; Interventions: Procedure: endoscopy | Arm Label: Standard care arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: endoscopy; Assigned to Arm(s): Active arm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Brief Summary: This trial will evaluate the efficacy and safety of brivaracetam (at doses of 5, 20 and 50 mg/day in twice a day administration) as add-on therapy in subjects with focal epilepsy.


Options:
A: Arm Label: Brivaracetam (BRV) 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam (BRV) 200 mg; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Lorazepam (LZP); Type: ACTIVE_COMPARATOR; Interventions: Drug: Lorazepam | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam (BRV) 100 mg, Brivaracetam (BRV) 200 mg | Intervention Type: DRUG; Name: Lorazepam; Assigned to Arm(s): Lorazepam (LZP)
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 20 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 50 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 100 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 20 mg/day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 50 mg/day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 100 mg/day
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 5 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 20 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 50 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 20 mg/day, Brivaracetam 5 mg/day, Brivaracetam 50 mg/day
D: Arm Label: Brivaracetam; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Brief Summary: This trial will evaluate the efficacy and safety of brivaracetam (at doses of 5, 20 and 50 mg/day in twice a day administration) as add-on therapy in subjects with focal epilepsy.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pregabalin add-on therapy | Arm Label: Pregabalin Level 1 (max 150 mg/day); Type: EXPERIMENTAL; Interventions: Drug: Pregabalin add-on therapy | Arm Label: Pregabalin Level 2 (max 600 mg day); Type: EXPERIMENTAL; Interventions: Drug: Pregabalin add-on therapy | Intervention Type: DRUG; Name: Pregabalin add-on therapy; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Pregabalin add-on therapy; Assigned to Arm(s): Pregabalin Level 1 (max 150 mg/day) | Intervention Type: DRUG; Name: Pregabalin add-on therapy; Assigned to Arm(s): Pregabalin Level 2 (max 600 mg day)
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gabapentin | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): B
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 5 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 20 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 50 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 20 mg/day, Brivaracetam 5 mg/day, Brivaracetam 50 mg/day
D: Arm Label: Study Drug Level 1; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin Dose Level 1 | Arm Label: Study Drug Level 2; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin Dose Level 2 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin Dose Level 1; Assigned to Arm(s): Study Drug Level 1 | Intervention Type: DRUG; Name: Pregabalin Dose Level 2; Assigned to Arm(s): Study Drug Level 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Multi-centre, Open-label, follow-on Study to CDP870-027, to Assess the Efficacy and Safety of Lyophilized CDP870 an Engineered Human Anti-TNF PEG Conjugate, as Additional Medication to Methotrexate, in the Treatment of Signs and Symptoms and Preventing Structural Damage in Patients With Active Rheumatoid Arthritis
Brief Summary: An open ended study in which patients who completed the double-blind study CDP870-027 \[NCT00152386\] are given Certolizumab Pegol (CZP) and assessed for signs and symptoms of Rheumatoid Arthritis (RA).


Options:
A: Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A
B: Arm Label: Certolizumab pegol 400 mg and placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Certolizumab pegol, Other: Placebo | Arm Label: Certolizumab pegol 200 mg and placebo; Type: EXPERIMENTAL; Interventions: Drug: Certolizumab pegol, Other: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Certolizumab pegol; Assigned to Arm(s): Certolizumab pegol 400 mg and placebo | Intervention Type: DRUG; Name: Certolizumab pegol; Assigned to Arm(s): Certolizumab pegol 200 mg and placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Certolizumab pegol 200 mg and placebo, Certolizumab pegol 400 mg and placebo, Placebo
C: Arm Label: Certolizumab Pegol; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol; Assigned to Arm(s): Certolizumab Pegol
D: Intervention Type: DRUG; Name: Certolizumab pegol (CDP870); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Multi-centre, Open-label, follow-on Study to CDP870-027, to Assess the Efficacy and Safety of Lyophilized CDP870 an Engineered Human Anti-TNF PEG Conjugate, as Additional Medication to Methotrexate, in the Treatment of Signs and Symptoms and Preventing Structural Damage in Patients With Active Rheumatoid Arthritis
Brief Summary: An open ended study in which patients who completed the double-blind study CDP870-027 \[NCT00152386\] are given Certolizumab Pegol (CZP) and assessed for signs and symptoms of Rheumatoid Arthritis (RA).


Options:
A: Arm Label: Placebo Plus Methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: Methotrexate, Other: Placebo | Arm Label: Rituximab plus Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: MabThera/Rituxan, Drug: Methotrexate | Intervention Type: DRUG; Name: MabThera/Rituxan; Assigned to Arm(s): Rituximab plus Methotrexate | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Placebo Plus Methotrexate, Rituximab plus Methotrexate | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Plus Methotrexate
B: Arm Label: Active 5 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active 10 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Sequence 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo Sequence 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active 5 mg | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active 10 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Sequence 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Sequence 2
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 3
D: Arm Label: Certolizumab Pegol; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol; Assigned to Arm(s): Certolizumab Pegol

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Multi-centre, Open-label, follow-on Study to CDP870-027, to Assess the Efficacy and Safety of Lyophilized CDP870 an Engineered Human Anti-TNF PEG Conjugate, as Additional Medication to Methotrexate, in the Treatment of Signs and Symptoms and Preventing Structural Damage in Patients With Active Rheumatoid Arthritis
Brief Summary: An open ended study in which patients who completed the double-blind study CDP870-027 \[NCT00152386\] are given Certolizumab Pegol (CZP) and assessed for signs and symptoms of Rheumatoid Arthritis (RA).


Options:
A: Arm Label: Certolizumab Pegol; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol; Assigned to Arm(s): Certolizumab Pegol
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra] | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1
C: Arm Label: Golimumab (CNTO 148) with Methotrexate (MTX); Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: MTX | Arm Label: Infliximab with MTX; Type: EXPERIMENTAL; Interventions: Drug: MTX, Drug: Infliximab | Arm Label: Placebo with MTX; Type: PLACEBO_COMPARATOR; Interventions: Drug: MTX, Drug: Placebo | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): Golimumab (CNTO 148) with Methotrexate (MTX) | Intervention Type: DRUG; Name: MTX; Assigned to Arm(s): Golimumab (CNTO 148) with Methotrexate (MTX), Infliximab with MTX, Placebo with MTX | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo with MTX | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): Infliximab with MTX
D: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Multi-centre, Open-label, follow-on Study to CDP870-027, to Assess the Efficacy and Safety of Lyophilized CDP870 an Engineered Human Anti-TNF PEG Conjugate, as Additional Medication to Methotrexate, in the Treatment of Signs and Symptoms and Preventing Structural Damage in Patients With Active Rheumatoid Arthritis
Brief Summary: An open ended study in which patients who completed the double-blind study CDP870-027 \[NCT00152386\] are given Certolizumab Pegol (CZP) and assessed for signs and symptoms of Rheumatoid Arthritis (RA).


Options:
A: Arm Label: Abatacept + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Arm Label: Placebo + Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Arm Label: Abatacept + Methotrexate Open Label; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label, Placebo + Methotrexate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Methotrexate
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept , Methotrexate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide | Intervention Type: DRUG; Name: Etanercept , Methotrexate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide; Assigned to Arm(s): 2
C: Arm Label: Certolizumab Pegol; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol; Assigned to Arm(s): Certolizumab Pegol
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra] | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Multi-centre, Open-label, follow-on Study to CDP870-027, to Assess the Efficacy and Safety of Lyophilized CDP870 an Engineered Human Anti-TNF PEG Conjugate, as Additional Medication to Methotrexate, in the Treatment of Signs and Symptoms and Preventing Structural Damage in Patients With Active Rheumatoid Arthritis
Brief Summary: An open ended study in which patients who completed the double-blind study CDP870-027 \[NCT00152386\] are given Certolizumab Pegol (CZP) and assessed for signs and symptoms of Rheumatoid Arthritis (RA).


Options:
A: Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: etanercept | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: sulfasalazine, Drug: hydroxychloroquine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: etanercept | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: sulfasalazine, Drug: hydroxychloroquine | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: sulfasalazine; Assigned to Arm(s): 2, 4 | Intervention Type: DRUG; Name: hydroxychloroquine; Assigned to Arm(s): 2, 4 | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): 1, 3
C: Arm Label: Certolizumab Pegol; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol; Assigned to Arm(s): Certolizumab Pegol
D: Arm Label: CP 690,550 1 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: CP 690,550 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: CP 690,550 15 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: CP 690,550 3 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: CP 690,550 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: CP-690,550 20 mg QD; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP 690,550 1 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP 690,550 10 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP 690,550 15 mg | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP 690,550 3 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP 690,550 5 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP-690,550 20 mg QD | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.
Brief Summary: Study N01175 was to compare overall effectiveness (efficacy and safety) of levetiracetam (LEV) versus the 2 older antiepileptic drugs (AEDs), sodium valproate extended release (VPA-ER) and carbamazepine controlled release (CBZ-CR) in the treatment of subjects with newly diagnosed epilepsy.


Options:
A: Arm Label: Levetiracetam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levetiracetam | Arm Label: Carbamazepine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbamazepine | Arm Label: Lamotrigine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lamotrigine | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Carbamazepine; Assigned to Arm(s): Carbamazepine | Intervention Type: DRUG; Name: Lamotrigine; Assigned to Arm(s): Lamotrigine
B: Intervention Type: DRUG; Name: phenobarbitone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: carbamazepine; Assigned to Arm(s): N/A
C: Arm Label: Levetiracetam; Type: EXPERIMENTAL; Interventions: Drug: Levetiracetam | Arm Label: Older Antepileptic Drugs; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbamazepine Controlled Release (CBZ-CR), Drug: Valproate Extended Release | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Carbamazepine Controlled Release (CBZ-CR); Assigned to Arm(s): Older Antepileptic Drugs | Intervention Type: DRUG; Name: Valproate Extended Release; Assigned to Arm(s): Older Antepileptic Drugs
D: Intervention Type: DRUG; Name: topiramate, phenytoin; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.
Brief Summary: Study N01175 was to compare overall effectiveness (efficacy and safety) of levetiracetam (LEV) versus the 2 older antiepileptic drugs (AEDs), sodium valproate extended release (VPA-ER) and carbamazepine controlled release (CBZ-CR) in the treatment of subjects with newly diagnosed epilepsy.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levetiracetam | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lamotrigine | Intervention Type: DRUG; Name: Lamotrigine; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): 1
B: Arm Label: Levetiracetam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levetiracetam | Arm Label: Carbamazepine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbamazepine | Arm Label: Lamotrigine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lamotrigine | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Carbamazepine; Assigned to Arm(s): Carbamazepine | Intervention Type: DRUG; Name: Lamotrigine; Assigned to Arm(s): Lamotrigine
C: Arm Label: Levetiracetam; Type: EXPERIMENTAL; Interventions: Drug: Levetiracetam | Arm Label: Carabamazepine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carabamazepine | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Carabamazepine; Assigned to Arm(s): Carabamazepine
D: Arm Label: Levetiracetam; Type: EXPERIMENTAL; Interventions: Drug: Levetiracetam | Arm Label: Older Antepileptic Drugs; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbamazepine Controlled Release (CBZ-CR), Drug: Valproate Extended Release | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Carbamazepine Controlled Release (CBZ-CR); Assigned to Arm(s): Older Antepileptic Drugs | Intervention Type: DRUG; Name: Valproate Extended Release; Assigned to Arm(s): Older Antepileptic Drugs

Answer: D